Stay Current at INTERPHEX - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Stay Current at INTERPHEX
An established show has several new programs that reflect the industry's current challenges.


Pharmaceutical Technology
Volume 34, Issue 4, pp. 14


Erik Greb
In addition to showcasing the latest innovations in pharmaceutical manufacturing equipment, INTERPHEX 2010 will help attendees stay current through various new presentations and discussions. Pharmaceutical Technology is partnering with INTERPHEX to present speakers from the US Food and Drug Administration, Rx–360, and PharmSource, a provider of business intelligence. Conference visitors will hear representatives of these groups discuss deficiencies in new drug applications, trends in supply-chain security, and the state of the outsourcing industry. Best of all, the speakers will take time to answer questions from the audience.

Although INTERPHEX is associated with small-molecule manufacturing, the conference is broadening its offerings for professionals involved in large-molecule production. BioPharm International, our sister publication, organized the keynote presentation this year about the effect of healthcare reform on the biopharmaceutical industry. MSNBC's Chris Matthews will moderate the discussion.

And each day, my colleagues and I will be conducting live interviews with various industry experts. We'll be giving you the scoop about quality-by-design implementation, packaging innovations, harmonization, and high-potency drugs. Our interviews will be videotaped and featured on our website after the conference.

INTERPHEX 2010 promises to keep attendees informed about the latest trends and innovations shaping the drug industry. I hope to see you there!

Check out PharmTech's preliminary program for its live video interviews at Interphex 2010

Erik Greb is an assistant editor of Pharmaceutical Technology.

Read Erik's blogs at http://blog.PharmTech.com/.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here